StockFetcher Forums · View by Author: (201 messages)  [ Display By: Date / Subject ]<< 1 2 3 4 5 ... 21 >> 
Stock Picks and Trading · Shills Swing N Daily
Nobody
msg #156513
4/8/2021 3:26:30 PM

Well played sir... Thanks
Don't laugh... I still have not gotten into crypts

Stock Picks and Trading · Pattern Watching
Nobody
msg #156448
modified
4/8/2021 3:12:08 PM

Eye on Bio




Stock Picks and Trading · Shills Swing N Daily
Nobody
msg #156447
4/8/2021 2:50:36 PM

shillllihs,

Do you use coinbase to buy such? Thanks

Stock Picks and Trading · Pattern Watching
Nobody
msg #156446
4/8/2021 2:49:28 PM

$AMRN

Above - from

https://www.fool.com/investing/2021/04/01/3-great-stocks-under-10-a-share/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article



1. Amarin -- $6 per share
This Irish biotech is my favorite value play right now. The company has an amazing drug, Vascepa, which reduces the risk of major adverse cardiovascular events by 25% in people who are on statin therapy. This is big news, as it suggests a new understanding of heart disease, the No. 1 killer of humans -- namely, that it's not enough to control cholesterol with statins. Vascepa reduces triglycerides (a type of fat in your blood). According to a Harvard study from 2018, by reducing triglycerides, Vascepa succeeded in reducing heart attacks, strokes, and deaths.

Why is the stock so cheap? I see two reasons. Number one is the fact that the COVID-19 lockdown has hampered sales growth. Doctors have to be informed about new medical breakthroughs, but that's hard to do in the midst of a lockdown, during which it has been hard to reach doctors. Despite that difficulty, Amarin increased revenue by 43% in 2020. I expect that rate to increase dramatically when the COVID-19 lockdown is over.

The main reason the stock is cheap, however, is that a couple of Amarin's patents were invalidated by a trial judge last year. That's opened the door to generic companies offering a version of Vascepa in the U.S., and cast a cloud over the company's growth story. All that doubt has been baked into the share price, and then some.

Nonetheless, I expect Vascepa sales to spike in the future. The market opportunity is massive, as an estimated 80 million people in Europe alone have cardiovascular disease. Amarin's patents in the rest of the world remain intact, and the European Commission is now allowing Amarin to market the drug to reduce the risk of cardiovascular events. And the invalidated patents in the U.S. only allow competition in the market to reduce triglycerides, not in the market to improve heart health. In short, Amarin has an approved drug that will save lives, a huge market opportunity, a strong competitive moat, and a price-to-sales (P/S) ratio of 3. For those reasons, I'm bullish.

Stock Picks and Trading · Pattern Watching
Nobody
msg #156443
modified
4/8/2021 2:25:47 PM






Stock Picks and Trading · Pattern Watching
Nobody
msg #156441
modified
4/8/2021 2:17:46 PM

there we go

slow but all good





Stock Picks and Trading · Pattern Watching
Nobody
msg #156364
4/1/2021 11:24:46 AM



Stock Picks and Trading · Pattern Watching
Nobody
msg #156363
modified
4/1/2021 11:18:04 AM




Biden Clean Energy stuff

Stock Picks and Trading · Shills Swing N Daily
Nobody
msg #156362
modified
4/1/2021 10:32:07 AM

klynn55,

I'd like to better myself... may I ask what is your primary source of news? Newspaper name or news outlet channel name....I'd like expose myself to same sources as you for a week or two and see try understand your point of view...

Thank you

Stock Picks and Trading · Pattern Watching
Nobody
msg #156346
3/31/2021 12:15:23 PM



FINIZ showing insider transaction --

StockFetcher Forums ·  · << 1 2 3 4 5 ... 21 >>

*** Disclaimer *** StockFetcher.com does not endorse or suggest any of the securities which are returned in any of the searches or filters. They are provided purely for informational and research purposes. StockFetcher.com does not recommend particular securities. StockFetcher.com, Vestyl Software, L.L.C. and involved content providers shall not be liable for any errors or delays in the content, or for any actions taken based on the content.


Copyright 2018 - Vestyl Software L.L.C.Terms of Service | License | Questions or comments? Contact Us
EOD Data sources: DDFPlus & CSI Data Quotes delayed during active market hours. Delay times are at least 15 mins for NASDAQ, 20 mins for NYSE and Amex. Delayed intraday data provided by DDFPlus


This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.